A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, Myeloma, News17 July 2024
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, Myeloma9 July 2024
MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPE26 June 2024
European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, Myeloma23 April 2024
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, Myeloma23 April 2024
Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myelomaAccess, MPE, Myeloma18 April 2024
MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulationAccess, MPE8 April 2024
European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, Myeloma21 March 2024
EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, Myeloma23 February 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, Myeloma22 February 2024
